Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diana Ferraro

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Journal of Neurology|February 15, 2022
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
Life (Basel, Switzerland)|June 26, 2025
Exploring the Role of Diabetes in ALS: A Population-Based Cohort StudyIlaria Martinelli, Giulia Gianferrari, Rebecca Santarelli, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neuroepidemiology|May 9, 2021
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, ItalyElisa Baldin, Corrado Zenesini, Ippazio Cosimo Antonazzo, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Journal of Neurology|February 15, 2022
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective studyAntonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese, et al.
Life (Basel, Switzerland)|June 26, 2025
Exploring the Role of Diabetes in ALS: A Population-Based Cohort StudyIlaria Martinelli, Giulia Gianferrari, Rebecca Santarelli, et al.
JAMA Neurology|August 8, 2018
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple SclerosisJordana Hughes, Vilija Jokubaitis, Alessandra Lugaresi, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 2, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosisNail Benallegue, Fabien Rollot, Pietro Iaffaldano, et al.
Neuroepidemiology|May 9, 2021
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, ItalyElisa Baldin, Corrado Zenesini, Ippazio Cosimo Antonazzo, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 20, 2022
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control StudyPietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
Journal of Neurology|May 28, 2024
Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progressionEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
Pharmacoeconomics|December 18, 2021
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United KingdomTimothy Spelman, William L Herring, Yuanhui Zhang, et al.
Pageof 13